A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty.
Alzheimer's
cognition
diagnosis
digital biomarker
memory
Journal
Frontiers in digital health
ISSN: 2673-253X
Titre abrégé: Front Digit Health
Pays: Switzerland
ID NLM: 101771889
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
09
2021
accepted:
01
11
2021
entrez:
9
12
2021
pubmed:
10
12
2021
medline:
10
12
2021
Statut:
epublish
Résumé
The One Card Learning Test (OCL80) from the Cogstate Brief Battery-a digital cognitive test used both in-person and remotely in clinical trials and in healthcare contexts to inform health decisions-has shown high sensitivity to changes in memory in early Alzheimer's disease (AD). However, recent studies suggest that OCL sensitivity to memory impairment in symptomatic AD is not as strong as that for other standardized assessments of memory. This study aimed to improve the sensitivity of the OCL80 to AD-related memory impairment by reducing the test difficultly (i.e., OCL48). Experiment 1 showed performance in healthy adults improved on the OCL48 while the pattern separation operations that constrain performance on the OCL80 were retained. Experiment 2 showed repeated administration of the OCL48 at short retest intervals did not induce ceiling or practice effects. Experiment 3 showed that the sensitivity of the OCL48 to AD-related memory impairment (Glass's Δ = 3.11) was much greater than the sensitivity of the OCL80 (Glass's Δ = 1.94). Experiment 4 used data from a large group of cognitively normal older adults to calibrate performance scores between the OCL80 and OCL48 using equipercentile equating. Together these results showed the OCL48 to be a valid and reliable test of learning with greater sensitivity to memory impairment in AD than the OCL80.
Identifiants
pubmed: 34881380
doi: 10.3389/fdgth.2021.780303
pmc: PMC8645569
doi:
Types de publication
Journal Article
Langues
eng
Pagination
780303Informations de copyright
Copyright © 2021 White, Schembri, Edgar, Lim, Masters and Maruff.
Déclaration de conflit d'intérêts
JW, AS, CE, and PM are/were full time employees of Cogstate Ltd, the company that distributed the Cogstate Brief Battery. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Prev Alzheimers Dis. 2021;8(3):267-276
pubmed: 34101783
Hippocampus. 2004;14(7):919-30
pubmed: 15382260
Neuropsychologia. 2013 Oct;51(12):2442-9
pubmed: 23313292
J Alzheimers Dis. 2020;76(1):261-274
pubmed: 32538841
Alzheimers Dement. 2019 Nov;15(11):1420-1426
pubmed: 31753288
J Alzheimers Dis Rep. 2021 Jun 03;5(1):443-468
pubmed: 34368630
Sci Rep. 2019 Mar 5;9(1):3543
pubmed: 30837580
Alzheimers Dement. 2015 Nov;11(11):1367-76
pubmed: 25858683
J Alzheimers Dis. 2007 Aug;12(1):23-35
pubmed: 17851192
J Int Neuropsychol Soc. 2021 Mar 23;:1-10
pubmed: 33752763
Ann Neurosci. 2013 Oct;20(4):155-6
pubmed: 25206041
Neurology. 2007 May 15;68(20):1718-25
pubmed: 17502554
Neuron. 2012 May 10;74(3):467-74
pubmed: 22578498
Alzheimers Dement (N Y). 2018 May 24;4:234-242
pubmed: 29955666
Psychol Sci. 2016 Feb;27(2):223-30
pubmed: 26674128
Science. 2008 Mar 21;319(5870):1640-2
pubmed: 18356518
Clin Pharmacol Ther. 2015 Nov;98(5):475-6
pubmed: 26272508
Alzheimers Dement (Amst). 2021 Jul 20;13(1):e12217
pubmed: 34295959
BMC Psychol. 2013 Dec 23;1(1):30
pubmed: 25566378
Alzheimers Dement. 2021 Apr;17(4):584-594
pubmed: 33650308
Neurology. 2020 Nov 3;95(18):e2577-e2585
pubmed: 32887774
Lancet Neurol. 2013 Apr;12(4):357-67
pubmed: 23477989
Trends Cogn Sci. 2019 Nov;23(11):938-951
pubmed: 31597601
Hum Psychopharmacol. 2008 Jul;23(5):425-36
pubmed: 18421801
J Alzheimers Dis. 2021;83(2):915-925
pubmed: 34366337
Transl Psychiatry. 2021 Apr 8;11(1):205
pubmed: 33833217
Alzheimers Dement. 2020 Oct;16(10):1426-1437
pubmed: 32715602
Arch Clin Neuropsychol. 2017 Mar 1;32(2):142-154
pubmed: 27932344
Alzheimers Dement (N Y). 2020 Jun 26;6(1):e12043
pubmed: 32607409
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
J Clin Psychopharmacol. 2015 Feb;35(1):22-33
pubmed: 25493397
Trends Neurosci. 2011 Oct;34(10):515-25
pubmed: 21788086
J Int Neuropsychol Soc. 2017 Oct;23(9-10):778-790
pubmed: 29198281
Neuroepidemiology. 2010;34(2):65-75
pubmed: 20016215
Proc Natl Acad Sci U S A. 2011 May 24;108(21):8873-8
pubmed: 21555581
Int Psychogeriatr. 2009 Aug;21(4):672-87
pubmed: 19470201
Brain. 2014 Jan;137(Pt 1):221-31
pubmed: 24176981
J Alzheimers Dis. 2021;79(4):1563-1573
pubmed: 33492293
J Prev Alzheimers Dis. 2021;8(4):513-519
pubmed: 34585227
J Clin Exp Neuropsychol. 2012;34(4):345-58
pubmed: 22248010
J Prev Alzheimers Dis. 2021;8(1):59-67
pubmed: 33336226
Arch Clin Neuropsychol. 2009 Mar;24(2):165-78
pubmed: 19395350